足三里穴位注射联合5-HT3受体拮抗剂在胃肠道肿瘤化疗相关恶心呕吐患者中的应用

Curative efficacy of Zusanli acupoint injection combined with 5-HT3 receptor antagonist in treatment of gastrointestinal tumor

目的探讨足三里穴位注射联合5-羟色胺(5-HT3)受体拮抗剂在胃肠道肿瘤化疗相关恶心呕吐患者中的应用效果。方法选择2016年5月至2018年5月在空军军医大学唐都医院消化内科治疗的80例胃肠道肿瘤患者为研究对象,按随机数表法将患者分为观察组和对照组各40例。对照组患者使用5-HT3受体拮抗剂治疗,观察组患者在对照组治疗的基础上应用足三里穴位注射治疗,实证患者选取蟾酥注射液,虚症患者选取黄芪注射液。7 d为一个疗程,两组均治疗两个疗程。比较两组患者治疗后的临床疗效、恶心程度、呕吐程度、呕吐持续时间、毒副反应总控制率和不良反应发生率。结果治疗后,观察组患者的治疗总有效率为92.5%,明显高于对照组的70.0%,差异有统计学意义(P<0.05);治疗后,观察组患者恶心、呕吐程度为0度者62.5%、1度者25.0%、2度者7.5%、3度者5.0%,均明显优于对照组的20.0%、5.0%、40.0%、35.0%,差异均有统计学意义(P<0.05);治疗后,观察组患者的呕吐持续时间为(4.3±1.8)d,明显短于对照组的(12.5±3.9)d,毒副反应总控制率为75.0%,明显高于对照组的40.0%,不良反应总发生率为5.0%,明显低于对照组的25.0%,差异均有统计学意义(P<0.05)。结论足三里穴位注射联合5-HT3受体拮抗剂治疗胃肠道肿瘤化疗相关恶心呕吐可有效改善患者恶心、呕吐情况,且不良反应少,值得临床推广应用。

Objective To investigate the application effect of Zusanli acupoint injection combined with 5-hydroxytryptamine(5-HT3)receptor antagonist in patients with gastrointestinal tumor-associated nausea and vomiting.Methods A total of 80 patients with gastrointestinal tumors,who admitted to Department of Gastroenterology,Tangdu Hospital of Air Force Military Medical University from May 2016 to May 2018,were selected and divided into the observation group and control group according to random number table method,with 40 patients in each group.The control group was treated with 5-HT3 receptor antagonist,and the patients in the observation group were treated with Zusanli acupoint injection on the basis of the control group,the patients of excess syndrome were treated with bufoni injection,and the patients of deficiency syndrome were treated with astragalus injection.Taking 7 days as a course of treatment,two courses of treatment were performed on both groups.The clinical efficacy,nausea degree,vomiting degree,vomiting duration,total control rate of adverse reactions and incidence of adverse reactions were compared between the two groups.Results After treatment,the total effective rate of the observation group was 92.5%,which was significantly higher than 70.0%of the control group(P<0.05);the degree of nausea and vomiting in the observation group showed 62.5%of 0 degree,25.0%of 1 degree,7.5%of 2 degree,5.0%of 3 degree,which were significantly better than corresponding 20.0%,5.0%,40.0%,35.0%in the control group(P<0.05);the duration of vomiting in the observation group was(4.3±1.8)d,which was significantly shorter than(12.5±3.9)d in the control group,the total control rate of adverse reactions was 75.0%versus 40.0%in the control group,and the overall incidence of adverse reactions was 5.0%versus 25.0%in the control group(all P<0.05).Conclusion Zusanli acupoint injection combined with 5-HT3 receptor antagonist has a significant effect on patients with gastrointestinal tumor chemotherapy-related nausea and vomiting,which can effectively improve patients'nausea and vomiting,with few adverse reactions,and is worthy of clinical application.